Literature DB >> 12543221

The GABA(A) receptor mediates the hypnotic activity of melatonin in rats.

Fang Wang1, Jingcai Li, Chunfu Wu, Jingyu Yang, Feng Xu, Qian Zhao.   

Abstract

The present investigation assessed whether hypnotic activity of melatonin was mediated by the GABA(A) receptor in rats. Electroencephalography (EEG) was measured in this experiment. Melatonin, at a dose of 10 mg/kg ip, showed a significant sleep-promoting effect in rats. Flumazenil (3.5 and 7 mg/kg), a specific antagonist of the benzodiazepine (BZP) recognition site on the GABA(A) receptor, and picrotoxin (2 and 4 mg/kg), the ligand of the picrotoxin site on the GABA(A) receptor, seemed to be devoid of intrinsic influence on each sleep parameter when used alone, but they significantly antagonized the melatonin-induced increase in total sleep time (TS), slow-wave sleep time (SWS) and paradoxical sleep time (PS), and the decrease in time to sleep onset (TSO) and wakefulness time (W). A significant interaction was shown between melatonin and flumazenil or picrotoxin. When bicuculline methiodide (2 and 4 mg/kg), a specific antagonist of the GABA binding site on the GABA(A) receptor, was used together with melatonin, the melatonin-induced increase in TS, SWS and PS, and the decrease in W were abolished. However, there was no interaction between melatonin and bicuculline methiodide on sleep parameters except PS. These results indicate that the hypnotic activity of melatonin may be linked to the GABA(A) receptor and mediated through the BZP recognition site, the picrotoxin site on the GABA(A) receptor and partially through the GABA binding site on the GABA(A) receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543221     DOI: 10.1016/s0091-3057(02)01045-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  10 in total

1.  Melatonin for sleep-disturbed children with autism spectrum disorders: can we really speak of a substitution treatment?

Authors:  Fabian Guénolé; Jean-Marc Baleyte
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-06-29       Impact factor: 4.785

Review 2.  Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease.

Authors:  Gianluca Tosini; Sharon Owino; Jean-Luc Guillaume; Ralf Jockers
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

3.  Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport.

Authors:  Richard J Naftalin; Philip Cunningham; Iram Afzal-Ahmed
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

Review 4.  Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.

Authors:  Stefano Comai; Gabriella Gobbi
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

5.  Impairment in behavioral sedation in rats during periods of elevated global geomagnetic activity.

Authors:  Neil M Fournier
Journal:  Int J Biometeorol       Date:  2019-06-17       Impact factor: 3.787

Review 6.  Analgesic, anxiolytic and anaesthetic effects of melatonin: new potential uses in pediatrics.

Authors:  Lucia Marseglia; Gabriella D'Angelo; Sara Manti; Salvatore Aversa; Teresa Arrigo; Russel J Reiter; Eloisa Gitto
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

Review 7.  Peripheral and central effects of melatonin on blood pressure regulation.

Authors:  Olga Pechanova; Ludovit Paulis; Fedor Simko
Journal:  Int J Mol Sci       Date:  2014-10-08       Impact factor: 5.923

Review 8.  The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.

Authors:  Andrea Contestabile; Salvatore Magara; Laura Cancedda
Journal:  Front Cell Neurosci       Date:  2017-03-07       Impact factor: 5.505

9.  Comparisons Between Successful Versus Unsuccessful Switches From Benzodiazepines or Zolpidem (Z-Drug) to Controlled-Release Melatonin in Patients With Major Depressive Disorder and Insomnia.

Authors:  Ji Hyun An; Mi Jin Park; Maurizio Fava; David Mischoulon; Hyewon Kim; Jihoon Jang; Jin Pyo Hong; Jun Sang Park; Hong Jin Jeon
Journal:  Front Psychiatry       Date:  2020-05-19       Impact factor: 4.157

10.  Melatonin attenuates morphine-induced conditioned place preference in Wistar rats.

Authors:  Fahad S Alshehri; Badrah S Alghamdi; Alqassem Y Hakami; Abdullah A Alshehri; Yusuf S Althobaiti
Journal:  Brain Behav       Date:  2021-10-28       Impact factor: 2.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.